WEDNESDAY, Jan. 12, 2022 (HealthDay News) – Babies conceived through infertility treatment are more likely to be born early and small. But there are reasons other than medically assisted reproduction to explain this difference, a new study concludes. “Rather than the infertility treatment itself, our new findings highlight the importance of parents’ underlying fertility problems… read on > read on >
All Food:
Medicare Proposes to Only Cover Alzheimer’s Drug Aduhelm for Use in Clinical Trials
It’s a move that could severely limit the number of people taking the controversial new Alzheimer’s drug Aduhelm: Medicare on Tuesday proposed to only cover the cost of the pricey medication for people enrolled in approved clinical trials. A final decision on coverage is expected later this year. The drug costs $28,200 per year, but… read on > read on >
More Olive Oil May Bring Longer Life: Study
Swapping out the butter or other artery-clogging fats in your diet for heart-healthy olive oil may add years to your life, researchers say. Folks who consume more than 1/2 a tablespoon of olive oil a day are less likely to die from heart disease, cancer, neurodegenerative diseases like Alzheimer’s or lung disease when compared to… read on > read on >
Four Factors in Midlife Predict a Healthy Old Age for Women
Examining a woman’s health in midlife can predict her health decades later, researchers say. Four specific factors — higher body mass index (BMI), smoking, arthritis and depressive symptoms — at age 55 are associated with clinically important declines in physical health 10 years later, a new study reports. “Age 55 to 65 may be a… read on > read on >
Medicare May Rethink Premium Hike for Pricey Alzheimer’s Drug
Medicare has been told to reassess a significant premium increase it had announced that largely stemmed from the expensive new Alzheimer’s drug Aduhelm. U.S. Health and Human Services Secretary Xavier Becerra’s directive, which was announced on Monday, comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to… read on > read on >
Do Not Use At-Home COVID Test Swabs in the Throat: FDA
Swabs that come with at-home rapid antigen COVID-19 tests should be used in the nose and not the throat, the U.S. Food and Drug Administration warns. It issued the warning on Twitter in response to reports that some people are using swabs intended for nasal samples to take samples from their throats and posting their… read on > read on >
Drug Combo Boosts Outcomes for Advanced Melanoma
For people newly diagnosed with advanced melanoma, a combination of two immunotherapy drugs can double the amount of time their cancer remains progression-free, a clinical trial has found. The treatment combines two drugs known as immune checkpoint inhibitors. One, called nivolumab (Opdivo), is already standard for advanced melanoma; the other, relatlimab, is not yet approved.… read on > read on >
Want to Avoid Glaucoma? Look at What You Eat
Eat right to protect your sight. That’s the advice of the Glaucoma Research Foundation, which offers its recipe for healthier eyes. Glaucoma is group of eye diseases that cause progressive vision loss through damage to the optic nerve. It is the second-leading cause of blindness. As with other health issues, good nutrition can make a… read on > read on >
FDA Shortens Time to Booster After Moderna Vaccine to 5 Months
Citing the rapid spread of the Omicron variant and the need for protection against it, U.S. federal health officials are shortening the recommended time between the second dose of the Moderna vaccine and a booster shot from six months down to five. “The country is in the middle of a wave of the highly contagious… read on > read on >
Aduhelm: Will Medicare Cover the Controversial Alzheimer’s Drug?
Following a months-long and unprecedented review, Medicare officials expect to announce within the next couple of weeks whether the program will cover the controversial Alzheimer’s drug Aduhelm. The drug’s benefits are in question and its annual price tag tops $28,000. The U.S. Centers for Medicare and Medicaid Services (CMS) tend to cover with little fanfare… read on > read on >